Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.


Clinical Trial Description

Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised patients. The poor prognosis of the disease is partly attributed to difficulties encountered with the diagnosis of this infection. Invasive sampling procedures are often precluded in these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently there has been increasing interest in the investigation of the lungs by noninvasive means including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls. ;


Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01247142
Study type Observational
Source Universitaire Ziekenhuizen Leuven
Contact
Status Completed
Phase N/A
Start date January 2011
Completion date July 2014

See also
  Status Clinical Trial Phase
Completed NCT01782131 - A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069) Phase 3
Recruiting NCT05138666 - Non-invasive Tools to Diagnose Invasive Aspergillosis Infections in ICU Patients With COVID-19 and Other Conditions. N/A
Not yet recruiting NCT02234739 - Voriconazole for IPA in Chinese Patients With COPD Phase 4
Completed NCT01615809 - Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia Phase 2
Completed NCT04267497 - Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study) Phase 1
Recruiting NCT05860387 - Early Diagnosis of Invasive Lung Aspergillosis
Withdrawn NCT01188759 - Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects Phase 3
Completed NCT00923832 - Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis N/A
Recruiting NCT05982912 - VOC in Breath Samples for the Diagnosis of IPA
Not yet recruiting NCT02100761 - CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients N/A
Recruiting NCT00986713 - Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Phase 4
Recruiting NCT05569824 - LFD of Aspergillus Antigen in Paediatrics
Not yet recruiting NCT04848831 - Diagnosis of Invasive Pulmonary Aspergillosis, Specific Testing in Bronchial Secretions Versus Bronchoalveolar Fluid
Completed NCT04077697 - Clinical and Prognostic Comparisons Between Invasive Pulmonary Aspergillosis With or Without Invasive Tracheobronchitis During Severe Influenza: a Retrospective Multicenter Cohort Study.
Completed NCT03672292 - Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis Phase 2
Recruiting NCT01499433 - Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Phase 4
Completed NCT00501098 - Prophylaxis of Fungal Invasive Infections in Leukemia Phase 2
Recruiting NCT03748069 - Influenza Associated Aspergillosis In-depth Investigation
Completed NCT02058316 - Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study
Terminated NCT03327727 - VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults Phase 2